Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A colony-stimulating factor is a signaling protein that promotes survival, proliferation, differentiation, or function of blood-forming cells. Therapeutic colony-stimulating factors are commonly produced using recombinant technology. Granulocyte colony-stimulating factors primarily increase neutrophil production. Examples include filgrastim, pegfilgrastim, and related biosimilar products.
read more about colonystimulating factor ...Granulocyte colony-stimulating factors are used to reduce the duration or complications of neutropenia in selected patients receiving myelosuppressive chemotherapy. They are also used in some bone marrow transplantation, stem-cell mobilization, severe chronic neutropenia, or radiation-exposure settings. Granulocyte-macrophage colony-stimulating factor products have narrower and different indications. The product, timing, and treatment goal depend on the clinical situation.
These medicines bind to specific receptors on hematopoietic progenitor cells and more mature blood cells. Granulocyte colony-stimulating factor signaling promotes neutrophil precursor proliferation, maturation, release, and function. Pegylation can slow drug clearance and extend the dosing interval. The increase in circulating neutrophils develops over time rather than immediately after injection.
Products are administered by subcutaneous injection, intravenous infusion, or specialized delivery devices according to the label. Timing relative to chemotherapy is carefully controlled because administration too close to cytotoxic treatment can be inappropriate. Blood counts and clinical response are monitored to guide duration or dose. Patients using home injections require training in storage, preparation, injection, and disposal.
Bone pain is common, and headache, injection-site reactions, or fever can also occur. Serious risks include splenic rupture, acute respiratory distress syndrome, severe allergic reactions, capillary leak syndrome, kidney inflammation, and sickle cell crisis. Very high white blood cell counts can occur, and growth-factor receptors have been found on some malignant cells. Left upper abdominal or shoulder pain, breathing difficulty, swelling, or severe weakness requires prompt assessment.
Yes. Filgrastim is a recombinant human granulocyte colony-stimulating factor that primarily stimulates neutrophil production.
Pegfilgrastim is a pegylated form with slower clearance and a longer duration of action. Their dosing schedules and approved uses are not identical.
Granulocyte colony-stimulating factors mainly increase neutrophils, not red blood cells. Erythropoiesis-stimulating agents are used for selected forms of anemia.
Yes. Bone pain is one of the most frequently reported effects and is related in part to increased bone marrow activity.
Filgrastim. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK559282/. Date Accessed August 6, 2026.
Pegfilgrastim. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK532893/. Date Accessed August 6, 2026.
NEUPOGEN (Filgrastim) Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193&type=display. Date Accessed August 6, 2026.
NEULASTA (Pegfilgrastim) Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce. Date Accessed August 6, 2026.
LEUKINE (Sargramostim) for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb9a3820-f31a-4dd9-bef4-97094c01a398. Date Accessed August 6, 2026.